Sutro results and extended cash runway
Sutro Biopharma reports Q4 2025 results with non-GAAP EPS -5.29, revenue $11.7M, beats estimates, extends cash runway into at least Q2 2028 after $110M equity raise
- Non-GAAP EPS -5.29 represents 36% YoY improvement, while revenue $11.7M declines 21% YoY in Q4 2025.
- Results beat both EPS and revenue estimates for the quarter.
- Company also posts FY25 results alongside Q4 2025 report today.
- Sutro initiates Phase 1 dosing of STRO-004 as part of its ADC development pipeline.
- Astellas-partnered immunostimulatory ADC (iADC) program advances, with initial clinical trial entry reported.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.